|
시장보고서
상품코드
1786980
세계의 레드 바이오테크놀러지 시장 규모, 점유율, 동향, 산업 분석 리포트 : 제품별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)Red Biotechnology Market Size, Share, Trends, Industry Analysis Report By Product (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products), By End Use, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 레드 바이오테크놀러지 시장 규모는 2034년까지 1조 4,157억 7,000만 달러에 달할 전망입니다. 이 리포트는 현재 시장 역학에 대한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
생명공학의 한 분야인 레드바이오테크놀러지는 인간의 건강 증진을 목적으로 하는 의료 및 의약품에 적용하는 데 초점을 맞추었습니다. 생체, 세포, 생물학적 과정을 이용하여 치료법, 진단법, 질병 예방법을 개발합니다. 이 분야는 복잡한 건강 문제에 대한 혁신적인 솔루션을 제공하며 현대 의학의 발전에 중요한 역할을 하고 있습니다.
레드바이오테크놀러지의 주요 용도 중 하나는 의약품 개발입니다. 연구자들은 유전공학을 활용해 인슐린, 백신, 모노클로널 항체 등 바이오의약품을 생산하고 있습니다. 유전자 재조합 DNA 기술로 유전자 재조합 박테리아를 이용한 인간 인슐린 생산이 가능해졌습니다. 마찬가지로 COVID-19를 위해 개발된 것과 같은 mRNA 백신과 치료제는 레드바이오테크놀러지가 팬데믹에 신속하게 대응할 수 있음을 보여주고 있습니다.
레드바이오테크놀러지는 진단 툴와 진단 기술도 강화합니다. 중합효소연쇄반응(PCR), 차세대염기서열분석(NGS) 등의 첨단 기술은 암, 감염 등의 질병을 조기에 정확하게 검출할 수 있게 해줍니다. 또한 레드바이오테크놀러지는 B형 간염, HPV, 독감 등의 질병을 예방하는 백신 개발을 지원하고 있습니다. 합성생물학은 백신 설계를 가속화하고, 바이오리액터는 대량 생산을 용이하게 합니다. 암 치료에서 레드바이오테크놀러지의 혁신 기술인 면역치료는 면역체계를 이용해 종양을 공격하는 것으로, CAR-T 세포와 같은 치료법이 특정 혈액암에서 괄목할 만한 성공을 거두고 있습니다.
레드 바이오테크 시장 보고서의 주요 내용
제품별로는 암, 자가면역질환, 감염성 질환 치료에 널리 사용되는 모노클로널 항체가 2024년 시장 매출 점유율 49.13%를 차지할 것으로 예측됩니다.
최종 용도별로는 제약 및 생명공학 기업이 2024년 제약 및 생명공학 기업이 생물제제 및 첨단 치료제의 기술 혁신, 임상 개발 및 상용화를 촉진하는 역할을 담당하며 큰 매출 점유율을 차지할 것으로 예측됩니다.
북미는 2024년 세계 레드 바이오테크놀러지 시장에서 34.16%의 점유율을 차지했습니다. 이러한 우위는 잘 구축된 의료 인프라, 높은 연구개발 투자, 암, 당뇨병, 심혈관 질환 등 만성질환의 유병률 증가에 기인합니다.
유럽 시장은 보편적 의료보험제도, 강력한 정부 및 EU의 재정 지원, 재생의료 및 바이오시밀러에 대한 집중으로 인해 2034년까지 상당한 점유율을 차지할 것으로 예측됩니다.
아시아태평양 시장은 의료비 지출 증가, 중산층 증가, 감염성 및 비감염성 질환의 높은 부담으로 인해 2025-2034년 CAGR 15.34%를 보일 것으로 예측됩니다.
레드 바이오테크놀러지 시장에서 세계의 주요 기업에는 Amgen Inc., AstraZeneca, Biogen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck KGaA, MavriX Bio, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 조사 방법
제4장 세계의 레드 바이오테크놀러지 시장 인사이트
- 시장 스냅숏
- 레드 바이오테크놀러지 시장 역학
- 촉진요인과 기회
- 맞춤형 의료의 수요 증가
- 암연구에 대한 투자 확대
- 억제요인과 과제
- 고비용
- 촉진요인과 기회
- PESTEL 분석
- 레드 바이오테크놀러지 시장 동향
- 밸류체인 분석
제5장 세계의 레드 바이오테크놀러지 시장 : 제품별
- 주요 조사 결과
- 서론
- 모노클로널 항체
- 폴리클로널 항체
- 재조합 단백질
- 백신
- 세포 기반 면역치료 제품
- 유전자 치료 제품
- 세포치료 제품
- 조직공학 제품
- 줄기세포
- 세포배양
- 바이러스 벡터
- 효소
- 키트와 시약
- 동물 모델
- 분자진단
- 기타
제6장 세계의 레드 바이오테크놀러지 시장 : 최종 용도별
- 주요 조사 결과
- 서론
- 학술연구기관
- CMO와 CRO
- 제약·바이오테크놀러지 기업
- 기타
제7장 세계의 레드 바이오테크놀러지 시장 : 지역별
- 주요 조사 결과
- 서론
- 레드 바이오테크놀러지 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 제품별, 2020-2034년
- 북미 : 최종 용도별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 제품별, 2020-2034년
- 유럽 : 최종 용도별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별, 2020-2034년
- 아시아태평양 : 최종 용도별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별, 2020-2034년
- 중동 및 아프리카 : 최종 용도별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별, 2020-2034년
- 라틴아메리카 : 최종 용도별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 사업 확대·인수 분석
- 사업 확대
- 인수
- 제휴/협업/협정/공개
제9장 기업 개요
- AstraZeneca
- Amgen Inc.
- Merck & Co
- Bristol-Myers Squibb
- Pfizer
- Biogen
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- MavriX Bio
- Regeneron Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company
The red biotechnology market size is expected to reach USD 1,415.77 billion by 2034, according to a new study by Polaris Market Research. The report "Red Biotechnology Market Size, Share, Trends, Industry Analysis Report By Product (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products), By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Red biotechnology, a branch of biotechnology, focuses on medical and pharmaceutical applications to improve human health. It involves the use of living organisms, cells, and biological processes to develop therapies, diagnostics, and preventive measures for diseases. This field plays a crucial role in advancing modern medicine, offering innovative solutions for complex health challenges.
One of the primary applications of red biotechnology is in the development of drugs. Researchers produce biopharmaceuticals such as insulin, vaccines, and monoclonal antibodies by leveraging genetic engineering. Recombinant DNA technology enables the production of human insulin using genetically modified bacteria. Similarly, mRNA vaccines and therapeutics, such as those developed for COVID-19, demonstrate how red biotechnology enables rapid responses to pandemics.
Red biotechnology also enhances diagnostic tools and techniques. Advanced techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), enable the early and accurate detection of diseases, including cancers and infectious diseases. Furthermore, red biotechnology supports vaccine development, which prevents diseases such as hepatitis B, HPV, and influenza. Synthetic biology accelerates vaccine design, while bioreactors facilitate large-scale production. In cancer treatment, immunotherapy, a red biotechnology innovation, harnesses the immune system to target tumors, with therapies such as CAR-T cells showing remarkable success in certain blood cancers.
Red Biotechnology Market Report Highlights
In terms of product, the monoclonal antibodies segment accounted for 49.13% of market revenue share in 2024 due to their widespread adoption in the treatment of cancer, autoimmune disorders, and infectious diseases.
Based on end use, the pharmaceutical & biotechnology companies segment accounted for a major revenue share in 2024 due to their role in driving innovation, clinical development, and commercialization of biologics and advanced therapies.
North America accounted for a 34.16% share of the global red biotechnology market in 2024. This dominance is attributed to established healthcare infrastructure, high R&D investments, and a growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders.
The market in Europe is projected to hold a substantial share by 2034 due to universal healthcare systems, strong government and EU funding, and a focus on regenerative medicine and biosimilars.
The market in Asia Pacific is projected to register a CAGR of 15.34% from 2025 to 2034, owing to increasing healthcare spending, a rising middle class, and a high burden of infectious and noncommunicable diseases.
A few global key players in the red biotechnology market include Amgen Inc.; AstraZeneca; Biogen; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck KGaA; MavriX Bio; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.
Polaris Market Research has segmented the red biotechnology market report on the basis of product, end use, and region:
By Product Outlook (Revenue, USD Billion, 2020-2034)
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Proteins
Vaccines
Cell-Based Immunotherapy Products
Gene Therapy Products
Cell Therapy Products
Tissue-Engineered Products
Stem Cells
Cell Culture
Viral Vector
Enzymes
Kits and Reagents
Animal Models
Molecular Diagnostics
Other
By End Use Outlook (Revenue, USD Billion, 2020-2034)
Academic Research Institutes
CMOs & CROs
Pharmaceutical & Biotechnology Companies
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Red Biotechnology Market Insights
- 4.1. Red Biotechnology Market - Market Snapshot
- 4.2. Red Biotechnology Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Demand for Personalized Medicine
- 4.2.1.2. Rising Investment in Cancer Research
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Red Biotechnology Market Trends
- 4.6. Value Chain Analysis
5. Global Red Biotechnology Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 5.3. Monoclonal Antibodies
- 5.3.1. Global Red Biotechnology Market, by Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)
- 5.4. Polyclonal Antibodies
- 5.4.1. Global Red Biotechnology Market, by Polyclonal Antibodies, by Region, 2020-2034 (USD Billion)
- 5.5. Recombinant Proteins
- 5.5.1. Global Red Biotechnology Market, by Recombinant Proteins, by Region, 2020-2034 (USD Billion)
- 5.6. Vaccines
- 5.6.1. Global Red Biotechnology Market, by Vaccines, by Region, 2020-2034 (USD Billion)
- 5.7. Cell-Based Immunotherapy Products
- 5.7.1. Global Red Biotechnology Market, by Cell-Based Immunotherapy Products, by Region, 2020-2034 (USD Billion)
- 5.8. Gene Therapy Products
- 5.8.1. Global Red Biotechnology Market, by Gene Therapy Products, by Region, 2020-2034 (USD Billion)
- 5.9. Cell Therapy Products
- 5.9.1. Global Red Biotechnology Market, by Cell Therapy Products, by Region, 2020-2034 (USD Billion)
- 5.10. Tissue-Engineered Products
- 5.10.1. Global Red Biotechnology Market, by Tissue-Engineered Products, by Region, 2020-2034 (USD Billion)
- 5.11. Stem Cells
- 5.11.1. Global Red Biotechnology Market, by Stem Cells, by Region, 2020-2034 (USD Billion)
- 5.12. Cell Culture
- 5.12.1. Global Red Biotechnology Market, by Cell Culture, by Region, 2020-2034 (USD Billion)
- 5.13. Viral Vector
- 5.13.1. Global Red Biotechnology Market, by Viral Vector, by Region, 2020-2034 (USD Billion)
- 5.14. Enzymes
- 5.14.1. Global Red Biotechnology Market, by Enzymes, by Region, 2020-2034 (USD Billion)
- 5.15. Kits and Reagents
- 5.15.1. Global Red Biotechnology Market, by Kits and Reagents, by Region, 2020-2034 (USD Billion)
- 5.16. Animal Models
- 5.16.1. Global Red Biotechnology Market, by Animal Models, by Region, 2020-2034 (USD Billion)
- 5.17. Molecular Diagnostics
- 5.17.1. Global Red Biotechnology Market, by Molecular Diagnostics, by Region, 2020-2034 (USD Billion)
- 5.18. Others
- 5.18.1. Global Red Biotechnology Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global Red Biotechnology Market, by End Use
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 6.3. Academic Research Institutes
- 6.3.1. Global Red Biotechnology Market, by Academic Research Institutes, by Region, 2020-2034 (USD Billion)
- 6.4. CMOs & CROs
- 6.4.1. Global Red Biotechnology Market, by CMOs & CROs, by Region, 2020-2034 (USD Billion)
- 6.5. Pharmaceutical & Biotechnology Companies
- 6.5.1. Global Red Biotechnology Market, by Pharmaceutical & Biotechnology Companies, by Region, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. Global Red Biotechnology Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Red Biotechnology Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Red Biotechnology Market Assessment, By Geography, 2020-2034 (USD Billion)
- 7.3. Red Biotechnology Market - North America
- 7.3.1. North America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.3.2. North America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.3.3. Red Biotechnology Market - U.S.
- 7.3.3.1. U.S.: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.3.3.2. U.S.: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.3.4. Red Biotechnology Market - Canada
- 7.3.4.1. Canada: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.3.4.2. Canada: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4. Red Biotechnology Market - Europe
- 7.4.1. Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.2. Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.3. Red Biotechnology Market - UK
- 7.4.3.1. UK: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.3.2. UK: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.4. Red Biotechnology Market - France
- 7.4.4.1. France: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.4.2. France: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.5. Red Biotechnology Market - Germany
- 7.4.5.1. Germany: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.5.2. Germany: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.6. Red Biotechnology Market - Italy
- 7.4.6.1. Italy: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.6.2. Italy: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.7. Red Biotechnology Market - Spain
- 7.4.7.1. Spain: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.7.2. Spain: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.8. Red Biotechnology Market - Netherlands
- 7.4.8.1. Netherlands: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.8.2. Netherlands: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.9. Red Biotechnology Market - Russia
- 7.4.9.1. Russia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.9.2. Russia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.4.10. Red Biotechnology Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.4.10.2. Rest of Europe: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5. Red Biotechnology Market - Asia Pacific
- 7.5.1. Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.2. Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.3. Red Biotechnology Market - China
- 7.5.3.1. China: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.3.2. China: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.4. Red Biotechnology Market - India
- 7.5.4.1. India: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.4.2. India: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.5. Red Biotechnology Market - Malaysia
- 7.5.5.1. Malaysia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.5.2. Malaysia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.6. Red Biotechnology Market - Japan
- 7.5.6.1. Japan: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.6.2. Japan: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.7. Red Biotechnology Market - Indonesia
- 7.5.7.1. Indonesia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.7.2. Indonesia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.8. Red Biotechnology Market - South Korea
- 7.5.8.1. South Korea: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.8.2. South Korea: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.9. Red Biotechnology Market - Australia
- 7.5.9.1. Australia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.9.2. Australia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.5.10. Red Biotechnology Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.5.10.2. Rest of Asia Pacific: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.6. Red Biotechnology Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.6.2. Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.6.3. Red Biotechnology Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.6.3.2. Saudi Arabia: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.6.4. Red Biotechnology Market - UAE
- 7.6.4.1. UAE: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.6.4.2. UAE: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.6.5. Red Biotechnology Market - Israel
- 7.6.5.1. Israel: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.6.5.2. Israel: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.6.6. Red Biotechnology Market - South Africa
- 7.6.6.1. South Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.6.6.2. South Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.6.7. Red Biotechnology Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.6.7.2. Rest of Middle East & Africa: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.7. Red Biotechnology Market - Latin America
- 7.7.1. Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.7.2. Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.7.3. Red Biotechnology Market - Mexico
- 7.7.3.1. Mexico: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.7.3.2. Mexico: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.7.4. Red Biotechnology Market - Brazil
- 7.7.4.1. Brazil: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.7.4.2. Brazil: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.7.5. Red Biotechnology Market - Argentina
- 7.7.5.1. Argentina: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.7.5.2. Argentina: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
- 7.7.6. Red Biotechnology Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Red Biotechnology Market, by Product, 2020-2034 (USD Billion)
- 7.7.6.2. Rest of Latin America: Red Biotechnology Market, by End Use, 2020-2034 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. AstraZeneca
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Amgen Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Merck & Co
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Bristol-Myers Squibb
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Pfizer
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Biogen
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. F. Hoffmann-La Roche Ltd
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Gilead Sciences, Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. MavriX Bio
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Regeneron Pharmaceuticals, Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Takeda Pharmaceutical Company
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
